Miromatrix Medical Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIRO research report →
Companywww.miromatrix.com
Miromatrix Medical Inc. , a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells.
- CEO
- Jeffrey James Ross
- IPO
- 2021
- Employees
- 76
- HQ
- Eden Prairie, MN, US
Price Chart
Valuation
- Market Cap
- $92.95M
- P/E
- -2.34
- P/S
- 97.49
- P/B
- 2.69
- EV/EBITDA
- -3.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 47.56%
- Op Margin
- -3172.17%
- Net Margin
- -3147.22%
- ROE
- -74.80%
- ROIC
- -99.98%
Growth & Income
- Revenue
- $953.47K · 2783.54%
- Net Income
- $-30,007,832 · -100.64%
- EPS
- $-1.45 · -98.63%
- Op Income
- $-30,245,734
- FCF YoY
- -52.51%
Performance & Tape
- 52W High
- $4.35
- 52W Low
- $0.91
- 50D MA
- $2.48
- 200D MA
- $1.72
- Beta
- 0.01
- Avg Volume
- 163.02K
Get TickerSpark's AI analysis on MIRO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 12, 23 | UNITED THERAPEUTICS Corp | other | 0 |
| Dec 12, 23 | Heine Lisa Wipperman | other | 66,943 |
| Dec 13, 23 | Heine Lisa Wipperman | sell | 67,413 |
| Dec 12, 23 | Maag Peter | other | 62,092 |
| Dec 13, 23 | Maag Peter | sell | 58,368 |
| Dec 12, 23 | ERB JOHN L | other | 56,260 |
| Dec 13, 23 | ERB JOHN L | sell | 54,201 |
| Dec 13, 23 | ERB JOHN L | sell | 25,000 |
| Dec 12, 23 | BUCKMAN PAUL | other | 52,593 |
| Dec 13, 23 | BUCKMAN PAUL | sell | 54,201 |
Our MIRO Coverage
We haven't published any research on MIRO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MIRO Report →